Lung cancer
Conditions
Interventions
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Be able to provide written informed consent (ICF), and be able to understand and agree to abide by the research requirements and evaluation schedule, and be able to cooperate in observing adverse events and curative effects. 2. No gender limit, aged 18-75 years at the time of signing the ICF. 3. Untreated advanced (III or IV) non-small cell lung cancer patients. 4. Have clear genetic test results. 5. ECOG PS: 0-2, and no signs of tumor progression in the last 2 weeks. 6. Expected survival time > 12 weeks. 7. The non-acute inflammatory period when the sample was collected.
Exclusion criteria
Exclusion criteria: 1. Patients receiving other approved systemic immunomodulators (including but not limited to interferon, interleukin 2, and tumor necrosis factor) 8 weeks prior to the first dose. 2. Active autoimmune disease that requires systemic treatment, and the investigator evaluates patients who are considered to have an impact on the study treatment. 3. Patients with long-term heavy use of hormones or other immunosuppressive agents, and the investigators assess that they have an impact on the study treatment. 4. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection, etc.: (1) Serious infection requiring hospitalization before the first administration or within 4 weeks of the peripheral blood collection time point, including but not limited to complications of infection, bacteremia or severe pneumonia; (2) Received oral or intravenous antibiotic therapy within 2 weeks before the first dose. 5. Known human immunodeficiency virus (HIV) infection. 6. Participate in another therapeutic clinical study at the same time. 7. Presence of a high-risk underlying medical condition or alcohol/drug abuse or dependence that affects the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung cancer tumor immune microenvironment heterogeneity; | — |
Countries
China
Contacts
Public ContactTian Panwen
West China Hospital of Sichuan University
Outcome results
None listed